KellBenx

About KellBenx

KellBenx, Inc. is a privately-held biotechnology company founded in 2010 with a focus on advancing women's healthcare through non-invasive prenatal diagnosis (NIPD). The company develops tests that extract clinically relevant information from blood to diagnose genetic and heritable disorders. Its core technology is designed to detect a wide range of genetic abnormalities, including aneuploidies, by capturing intact fetal DNA from a maternal blood sample. KellBenx's method involves using a monoclonal antibody to isolate nucleated fetal red blood cells for analysis.

The company was founded by a team that includes CEO Dr. Hassan Bennani and President Leonard H. Kellner. Dr. Bennani, who also serves as co-founder, has a background that includes an MD from Cheikh Anta Diop Medical School and extensive experience in sales, marketing, and business development within the medical and biotech fields. Mr. Kellner previously served as the President and CEO of Lenetix, a women's health lab acquired by Bio-Reference Laboratories. The leadership team also includes Chief Medical Advisor Dr. Jonathan Herman and Chief Scientific Officer Dr. Javad Khosravi.

Since its inception, KellBenx has secured multiple rounds of funding to finance clinical trials and laboratory operations. In April 2011, the company announced an initial funding round of $2.5 million. This was followed by a Series C financing round of $10 million in July 2013. The company's business model is centered on the development and commercialization of its proprietary diagnostic tests for the healthcare market, particularly serving Obstetricians, Gynecologists, and laboratories. The firm is headquartered in New York.